Stockscreener 앱 받기
6.71
7.70%
-0.56
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Millennium Management Trims Capricor Therapeutics (CAPR) Stake b - GuruFocus
Voting power over 1.67M Capricor (CAPR) shares is shared by three reporting parties. - Stock Titan
Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In - Stocktwits
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular DystrophySlideshow (NASDAQ:CAPR) 2026-10-13 - Seeking Alpha
Analysts Expect Breakeven For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Before Long - Simply Wall Street
Capricor reports 24-month data for Duchenne therapy deramiocel By Investing.com - Investing.com South Africa
What's Going On With Capricor Therapeutics Stock Monday? - Benzinga
Capricor Therapeutics (CAPR) Shares Drop 10% Despite Positive Du - GuruFocus
H.C. Wainwright Sees Mixed Signals in Capricor Therapeutics (CAP - GuruFocus
Capricor drops as deramiocel OLE data fails to quell regulatory concerns - Seeking Alpha
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November - Yahoo Finance
Roth Capital Maintains Neutral on Capricor Therapeutics (CAPR) A - GuruFocus
Capricor Therapeutics (CAPR) Reports Positive HOPE-3 Study Data on Deramiocel for Duchenne Muscular Dystrophy - GuruFocus
Capricor reports 24-month data for Duchenne therapy deramiocel - Investing.com
Capricor Therapeutics Reports Positive 24-Month HOPE-3 Data for Deramiocel in Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress - Yahoo Finance
After a year on placebo, patients’ arm-function decline rate was 76% lower on treatment - Stock Titan
Capricor Therapeutics, Inc. (CAPR) - Yahoo! Finance Canada
Capricor Therapeutics, Inc. (CAPR) - Yahoo! Finance Canada
Small-Cap Biotech Capricor Therapeutics (CAPR) Sees Elevated Sho - gurufocus.com
Capricor Therapeutics Shares Jump as Two-Year Data Bolster Duchenne Drug Case - finance.biggo.com
CAPR Stock Jumps As Analysts Hike Price Targets Into FDA Date - StocksToTrade
Capricor Therapeutics Stock Surges: What's Going On? - Benzinga
CAPR Stock Pops As Analysts Hike Targets Ahead FDA Call - timothysykes.com
CAPR Stock Jumps As Analysts Hike Price Targets Ahead FDA Call - StocksToTrade
CAPR Stock Jumps As Analysts Hike Targets Ahead Of FDA Date - timothysykes.com
CAPR Stock Jumps As Street Hikes Price Targets Into FDA Catalyst - StocksToTrade
Capricor Therapeutics, Inc. stock Analysis: Bearish Trend and Intraday Pause - The Cryptonomist
Capricor Therapeutics (CAPR) Shares Surge on Positive Phase 3 Da - gurufocus.com
Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ) - Seeking Alpha
Total equity of Capricor Therapeutics, Inc. – HAN:4LN2 - TradingView
Return on equity % of Capricor Therapeutics, Inc. – HAN:4LN2 - TradingView
Recover Investment Losses: Class Action Initiated Against Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - 巴士的報
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - Bluefield Daily Telegraph
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - globenewswire.com
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline - PR Newswire
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - PR Newswire
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action - TMX Newsfile
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. - GlobeNewswire
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - GlobeNewswire Inc.
CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - GlobeNewswire Inc.
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 28, 2026Contact Levi & Korsinsky - ACCESS Newswire
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 | FinancialContent - FinancialContent
CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, - globenewswire.com
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - Eastern Progress
CAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy - stocktwits.com
Capricor Therapeutics Shareholder Alert: ClaimsFiler - globenewswire.com
SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026CAPR - PR Newswire
4.22%
자본화:
|
볼륨(24시간):